{"id":"NCT01965158","sponsor":"Shionogi","briefTitle":"Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-29","primaryCompletion":"2015-01-22","completion":"2015-01-22","firstPosted":"2013-10-18","resultsPosted":"2017-05-30","lastUpdate":"2017-05-30"},"enrollment":547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-induced Constipation"],"interventions":[{"type":"DRUG","name":"Naldemedine","otherNames":["S 297995","SymproicÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Naldemedine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.","primaryOutcome":{"measure":"Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response","timeFrame":"12-week treatment period","effectByArm":[{"arm":"Naldemedine","deltaMin":47.6,"sd":null},{"arm":"Placebo","deltaMin":34.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0020"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":65,"countries":["United States","Austria","Czechia","Germany","Poland","Spain","United Kingdom"]},"refs":{"pmids":["34377150","34295186","33965574","32280263","32086791","31145214","28576452"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":271},"commonTop":["Diarrhoea","Abdominal pain"]}}